IL212919A - Highly concentrated concentrates with low viscosity - Google Patents

Highly concentrated concentrates with low viscosity

Info

Publication number
IL212919A
IL212919A IL212919A IL21291911A IL212919A IL 212919 A IL212919 A IL 212919A IL 212919 A IL212919 A IL 212919A IL 21291911 A IL21291911 A IL 21291911A IL 212919 A IL212919 A IL 212919A
Authority
IL
Israel
Prior art keywords
low viscosity
highly concentrated
concentrated suspensions
viscosity highly
suspensions
Prior art date
Application number
IL212919A
Other languages
English (en)
Hebrew (he)
Other versions
IL212919A0 (en
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of IL212919A0 publication Critical patent/IL212919A0/en
Publication of IL212919A publication Critical patent/IL212919A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL212919A 2008-11-16 2011-05-16 Highly concentrated concentrates with low viscosity IL212919A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11508008P 2008-11-16 2008-11-16
PCT/US2009/063852 WO2010056657A2 (en) 2008-11-16 2009-11-10 Low viscosity highly concentrated suspensions

Publications (2)

Publication Number Publication Date
IL212919A0 IL212919A0 (en) 2011-07-31
IL212919A true IL212919A (en) 2017-07-31

Family

ID=42170660

Family Applications (1)

Application Number Title Priority Date Filing Date
IL212919A IL212919A (en) 2008-11-16 2011-05-16 Highly concentrated concentrates with low viscosity

Country Status (7)

Country Link
US (2) US8779094B2 (enExample)
EP (1) EP2376522A4 (enExample)
JP (2) JP5711138B2 (enExample)
KR (1) KR20110103961A (enExample)
CA (1) CA2743789C (enExample)
IL (1) IL212919A (enExample)
WO (1) WO2010056657A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2170283T3 (en) 2007-06-22 2019-04-15 Univ Texas CREATION OF STABLE SUBMICRON Peptide OR PROTEIN PARTICLES BY THIN FILM FREEZING
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
CA2792517C (en) * 2010-03-09 2020-03-24 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations
US9445990B2 (en) * 2010-10-06 2016-09-20 Medtronic, Inc. TNF inhibitor formulation for use in implantable infusion devices
AU2012225277A1 (en) * 2011-03-10 2013-09-26 Board Of Regents, The University Of Texas System Protein nanoparticle dispersions
CA2951856A1 (en) 2011-10-28 2013-05-02 Integritybio Inc. Protein formulations containing amino acids
WO2013070692A1 (en) 2011-11-07 2013-05-16 Battelle Memorial Institute Processes for delivery of viscous drug therapies
MY188825A (en) * 2012-05-18 2022-01-06 Genentech Inc High-concentration monoclonal antibody formulations
HK1220120A1 (zh) * 2013-03-15 2017-04-28 Ansun Biopharma, Inc. 制造注射蛋白质微粒悬浮液的方法
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
CN103976947B (zh) * 2014-06-05 2016-08-17 段明星 一种含酶油悬浮剂及其制备方法与应用
AU2015325055B2 (en) 2014-10-01 2021-02-25 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
JP5774190B1 (ja) * 2014-12-12 2015-09-09 ジーンメディカル株式会社 皮下注射用剤及び皮下注射用剤を含有する注射器の製造方法
EP3231433B1 (en) * 2014-12-12 2023-12-27 Motejo. Ltd Agent for hypodermic injection
MA46466A (fr) * 2016-10-06 2019-08-14 Amgen Inc Formulations pharmaceutiques de protéines à viscosité réduite
AU2017364077A1 (en) 2016-11-22 2019-06-20 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
AU2018306303A1 (en) 2017-07-25 2020-02-20 Elektrofi, Inc. Formation of particles including agents
US12115262B2 (en) 2018-05-24 2024-10-15 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
KR102051808B1 (ko) 2018-07-23 2019-12-04 주식회사 종근당 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물
AU2020214626B2 (en) 2019-01-31 2025-10-16 Elektrofi, Inc. Particle formation and morphology
KR20210125032A (ko) 2019-02-05 2021-10-15 린디 바이오사이언시스, 아이엔씨. 세포 배양 성분 및 액체 세포 배양 배지로부터 이를 단리하는 방법
US20200376128A1 (en) * 2019-06-01 2020-12-03 Lupin Holdings B.V. Monodisperse resorbable polyester polymer compositions, systems, and methods
JP7781743B2 (ja) * 2019-09-13 2025-12-08 エレクトロフィ，インコーポレイテッド 疾患の処置のための治療用生物学的作用剤の送達のための組成物及び方法
JP2023522627A (ja) 2020-04-17 2023-05-31 エレクトロフィ，インコーポレイテッド 連続的な液滴形成及び脱水によって粒子を形成する方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795516A (fr) 1972-02-17 1973-08-16 Ciba Geigy Preparations de peptides huileuses et injectables et procede pour leur preparation
US4310516A (en) 1980-02-01 1982-01-12 Block Drug Company Inc. Cosmetic and pharmaceutical vehicle thickened with solid emulsifier
EP0079143A3 (en) 1981-10-20 1984-11-21 Adnovum Ag Pseudoplastic gel transfer
US4594108A (en) 1983-09-19 1986-06-10 The Dow Chemical Company Highly pseudoplastic polymer solutions
US5411951A (en) 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
US5288479A (en) 1989-01-17 1994-02-22 Sterling Drug, Inc. Extrudable elastic oral pharmaceutical gel compositions and metered dose dispensers containing them and method of making and method of use thereof
SE465950B (sv) 1989-10-23 1991-11-25 Medinvent Sa Kombination av ett aggregat partikelformat, kristallint eller frystorkat laekemedel med en pseudoplastisk gel foer beredning av ett injicerbart preparat samt foerfarande foer dess framstaellning
US5300302A (en) 1990-10-04 1994-04-05 Nestec S.A. Pharmaceutical composition in gel form in a dispensing package
YU87892A (sh) 1991-10-01 1995-12-04 Eli Lilly And Company Lilly Corporate Center Injektibilne formulacije produženog otpuštanja i postupci za njihovo dobijanje i primenu
WO1993020134A1 (en) 1992-03-30 1993-10-14 Alza Corporation Additives for bioerodible polymers to regulate degradation
MX9301823A (es) 1992-03-30 1994-01-31 Alza Corp Composicion para el suministro de liberacion controlado de un agente biologicamente activo.
US5512293A (en) 1992-07-23 1996-04-30 Alza Corporation Oral sustained release drug delivery device
SE9203594D0 (sv) 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
WO1995034285A1 (en) 1994-06-13 1995-12-21 Alza Corporation Dosage form for administering drug in liquid formulation
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US5916582A (en) 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
CA2259403A1 (en) 1996-07-03 1998-01-08 Alza Corporation Non-aqueous protic peptide formulations
IN184589B (enExample) 1996-10-16 2000-09-09 Alza Corp
US7393630B2 (en) * 1997-12-16 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Use of microparticles combined with submicron oil-in-water emulsions
WO2000045790A2 (en) 1999-02-08 2000-08-10 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
FR2809309B1 (fr) * 2000-05-23 2004-06-11 Mainelab Microspheres a liberation prolongee pour administration injectable
WO2002043580A2 (en) 2000-10-27 2002-06-06 Epic Therapeutics, Inc. Production of microspheres
US20040022861A1 (en) 2001-01-30 2004-02-05 Williams Robert O. Process for production of nanoparticles and microparticles by spray freezing into liquid
JP4724354B2 (ja) * 2001-02-23 2011-07-13 ジェネンテック， インコーポレイテッド 注射用の崩壊性ポリマー
EP1492554B1 (en) * 2001-06-21 2019-08-21 Althea Technologies, Inc. Spherical protein particles
AU2003291527A1 (en) 2002-12-31 2004-07-29 Nektar Therapeutics Antibody-containing particles and compositions
DK1610820T4 (da) * 2003-04-04 2013-11-04 Genentech Inc Høj-koncentration antistof- og proteinformuleringer
EP1663158A2 (en) 2003-06-24 2006-06-07 Baxter International Inc. Specific delivery of drugs to the brain
KR101137785B1 (ko) 2003-07-18 2012-04-25 백스터 인터내셔널 인코포레이티드 제어된 상 분리에 의해 제조된 작은 구형 입자의 제조방법, 이용 방법 및 조성물
FR2862536B1 (fr) * 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
MXPA06012992A (es) 2004-05-12 2007-02-12 Baxter Int Microesferas que comprenden proteina y que muestran inyectabilidad en altas concentraciones de este agente.
US20060141040A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
WO2006083761A2 (en) * 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US20070015689A1 (en) 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
EP1968550A2 (en) 2005-12-16 2008-09-17 University Of Kansas Nanoclusters for delivery of therapeutics
WO2007072982A1 (en) 2005-12-20 2007-06-28 Fujifilm Corporation Protein nanoparticles and the use of the same
US20080102128A1 (en) * 2006-07-28 2008-05-01 Flamel Technologies, Inc. Modified-release microparticles based on amphiphilic copolymer and on active principles(s) and pharmaceutical formulations comprising them
DK2170283T3 (en) 2007-06-22 2019-04-15 Univ Texas CREATION OF STABLE SUBMICRON Peptide OR PROTEIN PARTICLES BY THIN FILM FREEZING
CN101081882A (zh) * 2007-07-06 2007-12-05 天津大学 大分子印迹交联聚乙烯基吡咯烷酮微球及低温悬浮聚合制备方法
JP2009173610A (ja) 2008-01-28 2009-08-06 Fujifilm Corp タンパク質ナノ粒子
EP2259798B1 (en) 2008-03-05 2013-12-11 Baxter International Inc. Surface-modified particles and methods for targeted drug delivery
AU2009244742B2 (en) 2008-05-09 2014-11-06 South Dakota State University Method of forming non-immunogenic hydrophobic protein nanoparticles and uses therefor
US20100009007A1 (en) 2008-07-10 2010-01-14 Baxter International Inc. Non-covalent modification of microparticles and process of preparing same
US8323685B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
WO2010100200A2 (en) 2009-03-05 2010-09-10 Novartis Ag Lyophilised antibody formulation

Also Published As

Publication number Publication date
EP2376522A2 (en) 2011-10-19
WO2010056657A8 (en) 2010-08-26
CA2743789C (en) 2017-10-31
JP2012508744A (ja) 2012-04-12
CA2743789A1 (en) 2010-05-20
US20140378370A1 (en) 2014-12-25
US20110280864A1 (en) 2011-11-17
JP5711138B2 (ja) 2015-04-30
IL212919A0 (en) 2011-07-31
JP2015083582A (ja) 2015-04-30
EP2376522A4 (en) 2013-12-25
WO2010056657A3 (en) 2010-10-14
WO2010056657A2 (en) 2010-05-20
US8779094B2 (en) 2014-07-15
KR20110103961A (ko) 2011-09-21

Similar Documents

Publication Publication Date Title
IL212919A0 (en) Low viscosity highly concentrated suspensions
TWI367207B (en) Substituted pyrrolidine-2-carboxamides
EP2280616A4 (en) BODY FOR BABY
IL208990A0 (en) Novel phenylimidazopyrazines
ZA201103171B (en) Novel uses
EP2285758A4 (en) DISPOSABLE PACKAGING FOR FERTILIZER-PESTICIDE
AU322712S (en) Eyewear
IL208281A0 (en) Substituted cyclohexyldiamines
EP2313147A4 (en) crimping
IL209175A0 (en) Substituted qunazolines
EP2351716A4 (en) GLASS
AU322710S (en) Eyewear
EP2403896A4 (en) POLYAMIDE OF LIGHT VISCOSITY
EP2233305A4 (en) GRAPHIC PRINTER
AU322708S (en) Eyewear
GB0815068D0 (en) Insectical combinations
AU322711S (en) Eyewear
AU322709S (en) Eyewear
GB0800389D0 (en) Gileo hang-it
GB0800161D0 (en) Rota-board
AU322707S (en) Eyewear
GB0813878D0 (en) Biocapsulate suspensions
AU3977P (en) PARV01 Myoporum parvifolium
AU3935P (en) DPV308 Dianella prunina
AU4098P (en) NPW2 Dianella tasmanica

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed